A citation-based method for searching scientific literature

Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz, Rick Hoover, Sai-Hong Ignatius Ou, Ravi Salgia, Tim Brennan, Zachary R Chalmers, Savina Jaeger, Alan Huang, Julia A Elvin, Rachel Erlich, Alex Fichtenholtz, Kyle A Gowen, Joel Greenbowe, Adrienne Johnson, Depinder Khaira, Caitlin McMahon, Eric M Sanford, Steven Roels, Jared White, Joel Greshock, Robert Schlegel, Doron Lipson, Roman Yelensky, Deborah Morosini, Jeffrey S Ross, Eric Collisson, Malte Peters, Philip J Stephens, Vincent A Miller. Cancer Discov 2015
Times Cited: 481



Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier, George Vande Woude. Nat Rev Cancer 2012
Times Cited: 1067




List of shared articles



Times cited

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Magda Bahcall, Cloud P Paweletz, Yanan Kuang, Luke J Taus, Taebo Sim, Nam Doo Kim, Kshiti H Dholakia, Christie J Lau, Prafulla C Gokhale, Pratik R Chopade,[...]. Mol Cancer Ther 2022
1

Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination.
Feng Wang, Yang Liu, Wanglong Qiu, Elaine Shum, Monica Feng, Dejian Zhao, Deyou Zheng, Alain Borczuk, Haiying Cheng, Balazs Halmos. Cancer Res 2022
2

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.
Juan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Camila Ordoñez, Elvira Jaller, Leonardo Rojas, Alessandro Russo,[...]. Ther Adv Respir Dis 2022
2

CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway.
Anqi Wang, Wen Yang, Yue Li, Yang Zhang, Jieqi Zhou, Ruochen Zhang, Weijie Zhang, Jianjie Zhu, Yuanyuan Zeng, Zeyi Liu,[...]. Cell Commun Signal 2022
3

Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
Alessa Fischer, Lorenz Bankel, Stefanie Hiltbrunner, Markus Rechsteiner, Jan H Rüschoff, Elisabeth Jane Rushing, Christian Britschgi, Alessandra Curioni-Fontecedro. Target Oncol 2022
0

Oncogene alterations in non-small cell lung cancer-have we MET a new target?
Wolfram C M Dempke, Susanne Reuther, Zohdy Hamid, Nils H Thoennissen. Transl Lung Cancer Res 2022
0

Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L Reckamp, Sunil Sharma, Hirak Der-Torossian, James G Christensen,[...]. Target Oncol 2022
0

Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer.
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J Peters, Omidreza Firuzi. Crit Rev Oncol Hematol 2021
14

Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target.
Danish Safi, Taher Abu Hejleh, Muhammad Furqan. Transl Lung Cancer Res 2021
3